Prostate Cancer - Episode 5

Episode 5 - Pharmacoeconomic Considerations

During this discussion, Jeffrey D. Dunn, PharmD, MBA, explains how the rapid development of specialty drugs for the treatment of castration-resistant prostate cancer (CRPC) has increased the amount of pharmacoeconomic spending in the United States.

Because there are several options available, and because clinicians have different treatment preferences, Michael Kolodziej, MD, discusses why it is necessary to determine a proper sequencing plan before administering treatment.

Raoul S. Concepcion, MD, agrees that drug sequencing is a major challenge. However, he believes that because so many treatment options are available, clinicians need to individualize therapy when treating patients with CRPC.

Dr Dunn, Dr Concepcion, and David Quinn, MD, review the costs of new agents and discuss why it is important for insurers to provide coverage toward research that tests drug sequencing.